Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ning Jiang
University of Texas, Austin, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Immune Arch, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The CI and her spouse are co-founders of Immune Arch, Inc. The company is involved in the development and commercialization of technologies related to immune repertoire sequencing and high-throughput immune analysis and engineering for clinical and research purposes. The CI is Scientific Advisor for Immune Arch, Inc. The PI's spouse is CEO and holds primary equity ownership in the company. Immune Arch, Inc. may license technologies that were developed by the PI through her work at the university.
An integrated therapeutic T cell receptor screening platform for adoptive cell therapy in cancer
Narrative This project aims to an integrated technology for speeding up the process of therapeutic T cell receptor identification and validation. This is highly relevant to both highly mutated cancers as well as cancers with low mutation burden. The success of this project will make it possible to test combinatorial T cell receptor re-directed adoptive cell transfer therapy in animal models and future clinical trials. Expected results not only establish the foundation for a paradigm shift for future cancer immune therapy, but also make T cell receptor based adoptive cell transfer therapy available to more patients.
Filed on January 18, 2019.
Tell us what you know about Ning Jiang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Ning Jiang filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ning Jiang | University of Texas, Austin | Conflict of Interest | ImmuDX, LLC | Value cannot be readily determined |
| Ning Jiang | University of Texas, Austin | Conflict of Interest | Immune Arch, Inc. | Value cannot be readily determined |
| Ning Jiang | University of Texas, Austin | Conflict of Interest | ImmuDX, LLC | Value cannot be readily determined |
Other search results for: “Ning Jiang”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ning Jiang | University of Texas, Austin | Financial Disclosure | Zhongyuan Union Genetic Technology Co.,Ltd | |
| Ning Jiang | University of Texas, Austin | Financial Disclosure | ImmuDX, LLC | |
| Ning Jiang | University of Texas, Austin | Financial Disclosure | ImmuDX, LLC |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.